Marketdash
Back to News

Pharma Bro Calls His Shot: Shkreli Targets Biotech Stock Hours Before Trial Results

MarketDash Editorial Team
13 days ago
Martin Shkreli publicly announced he's shorting Capricor Therapeutics, predicting its lead drug candidate will fail just days before crucial trial results. The stock dropped over 17% on the news.

Capricor Therapeutics Inc. (CAPR) had a rough Monday after Martin Shkreli, the infamous "Pharma Bro," decided to make the biotech his latest short target. The timing? Spectacularly dramatic, even by Shkreli standards.

The Short Call Heard Round The Market

Shkreli took to social media to announce his bearish position on Capricor, specifically targeting the company's cell therapy approach and its clinical trial data for deramiocel, its lead candidate. His main thesis: the upcoming trial results are doomed.

"In the next, few days the HOPE-3 (aka COPE-3) study will report its data. It will not work. This is the company's only asset," Shkreli declared.

He didn't stop there. The controversial former pharmaceutical executive raised concerns about cell trafficking challenges and potential safety issues with the donor heart-derived cells used in the treatment. His price target? Around $2 per share, which would represent a massive decline from current levels.

The market reacted swiftly. Capricor shares plunged over 17% following the commentary, trading at $4.75 by Monday's close.

MarketDash reached out to Capricor for comment but didn't receive a response before publication.

Meanwhile, Back At The Lab

In what might be filed under "interesting timing," Capricor also announced positive developments on Monday. The company unveiled a scalable framework for loading therapeutic oligonucleotides into exosomes, which management believes could solve a critical manufacturing bottleneck.

The approach could provide a practical pathway to produce clinically relevant quantities of loaded exosomes, addressing a key hurdle for advancing the platform into later-stage trials.

Chief Executive Linda Marbán emphasized that the findings highlight the strength and versatility of Capricor's exosome technology and its potential to address a broad range of diseases.

Whether this alternative platform matters to investors likely depends on what happens with those HOPE-3 results Shkreli is betting against. With the data expected in days, we won't have to wait long to see if the Pharma Bro's prediction plays out.

Back to News

Pharma Bro Calls His Shot: Shkreli Targets Biotech Stock Hours Before Trial Results

MarketDash Editorial Team
13 days ago
Martin Shkreli publicly announced he's shorting Capricor Therapeutics, predicting its lead drug candidate will fail just days before crucial trial results. The stock dropped over 17% on the news.

Capricor Therapeutics Inc. (CAPR) had a rough Monday after Martin Shkreli, the infamous "Pharma Bro," decided to make the biotech his latest short target. The timing? Spectacularly dramatic, even by Shkreli standards.

The Short Call Heard Round The Market

Shkreli took to social media to announce his bearish position on Capricor, specifically targeting the company's cell therapy approach and its clinical trial data for deramiocel, its lead candidate. His main thesis: the upcoming trial results are doomed.

"In the next, few days the HOPE-3 (aka COPE-3) study will report its data. It will not work. This is the company's only asset," Shkreli declared.

He didn't stop there. The controversial former pharmaceutical executive raised concerns about cell trafficking challenges and potential safety issues with the donor heart-derived cells used in the treatment. His price target? Around $2 per share, which would represent a massive decline from current levels.

The market reacted swiftly. Capricor shares plunged over 17% following the commentary, trading at $4.75 by Monday's close.

MarketDash reached out to Capricor for comment but didn't receive a response before publication.

Meanwhile, Back At The Lab

In what might be filed under "interesting timing," Capricor also announced positive developments on Monday. The company unveiled a scalable framework for loading therapeutic oligonucleotides into exosomes, which management believes could solve a critical manufacturing bottleneck.

The approach could provide a practical pathway to produce clinically relevant quantities of loaded exosomes, addressing a key hurdle for advancing the platform into later-stage trials.

Chief Executive Linda Marbán emphasized that the findings highlight the strength and versatility of Capricor's exosome technology and its potential to address a broad range of diseases.

Whether this alternative platform matters to investors likely depends on what happens with those HOPE-3 results Shkreli is betting against. With the data expected in days, we won't have to wait long to see if the Pharma Bro's prediction plays out.

    Pharma Bro Calls His Shot: Shkreli Targets Biotech Stock Hours Before Trial Results - MarketDash News